Skip to main content
OpenTrials

Clinical trial condition

Blasts Under 20 Percent of Bone Marrow Nucleated Cells

Explore clinical trials studying Blasts Under 20 Percent of Bone Marrow Nucleated Cells. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Blasts Under 20 Percent of Bone Marrow Nucleated Cells trial results

Recruiting

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434

Conditions
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, +17 more
Locations
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • OHSU Knight Cancer Institute Portland, Oregon, United States
  • University of Utah Salt Lake City, Utah, United States
  • Fred Hutchinson cancer research center Seattle, Washington, United States
View Trial Details

Related conditions